Drug Profile


Alternative Names: Anti-KIR (1-7F9); Anti-KIR monoclonal antibody - Innate Pharma; BMS-986015; IPH-21; IPH-2101; IPH-2102; LIRI; NN 1975

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Bristol-Myers Squibb; Innate Pharma; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action KIR receptor antagonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Myelodysplastic syndromes
  • Phase I Haematological malignancies; Multiple myeloma; Solid tumours
  • Preclinical Lymphoma
  • Discontinued Hepatitis C

Most Recent Events

  • 05 Dec 2016 Interim efficacy data from a phase II trial in Acute myeloid leukaemia released by Innate Pharma
  • 17 Nov 2016 Innate Pharma completes the phase II (EFFIKIR) trial in Acute myeloid leukaemia in France (EudraCT2012-001594-93)
  • 12 Nov 2016 Efficacy data from expansion cohort of phase I/II trial in Solid tumours released by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top